Clinical trials: Type 2 Diabetes
Diabetes Mellitus, Type 2
Pharmacokinetics, Pharmacodynamics, and Safety of Alogliptin in Children, Adolescents and Adults With Type 2 Diabetes Mellitus
The purpose of this study is to determine the pharmacokinetic and safety profile of alogliptin in children, adolescents, and adults with type 2 diabetes mellitus.
- Trial name
- NCT00957268
- Testing
- Alogliptin
- Where
- 7 sites in United States
- Volunteers
- 46 people
- Sponsor
- Takeda
Type 2 Diabetes Mellitus, Healthy
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
The objective of this proposal is to provide quantitative dose-response data for effects of GLP-1 on myocardial glucose uptake in healthy control subjects and obese type 2 diabetic subjects, in support of the design of later…
- Trial name
- NCT01607450
- Testing
- GLP-1 Low Dose, GLP-1 Mid-Range Dose, GLP-1 High Dose
- Where
- United States
- Volunteers
- 33 people, healthy volunteers welcome
- Sponsor
- Indiana University
Type 2 Diabetes
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-8655 in Participants With Type 2 Diabetes (MK-8655-002)
This study will assess the initial safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-8655, after single and multiple daily oral administrations to participants with Type 2 Diabetes (T2DM).
- Trial name
- NCT01640873
- Testing
- MK-8655
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes Mellitus
Effects of Dapagliflozin 10 mg on Insulin Resistance in Patients With Type 2 Diabetes Mellitus
This is an 8-week, single centre, randomized, parallel-group, double-blind, placebo-controlled Phase IV study to evaluate the effect of dapagliflozin on tissue specific insulin sensitivity in patients with Type 2 diabetes mellitus
- Trial name
- DERISC (NCT02426541)
- Testing
- Dapagliflozin
- Where
- Finland
- Volunteers
- 55 people
- Sponsor
- AstraZeneca
Diabetes
Mechanisms of Glucose Lowering Effect of Colesevelam HCl
The mechanism by which colesevelam HCl lowers glucose is not known. Knowledge of the potential mechanism of action is important for defining the role of the drug among oral antidiabetic agents available for use in subjects with…
- Trial name
- NCT00596427
- Testing
- Colesevelam HCL
- Where
- 3 sites in United States
- Volunteers
- 60 people
- Sponsor
- Carine Beysen
Type 2 Diabetes Mellitus
Double-blind Ipragliflozin Add-on Study in Japanese Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Sitagliptin (MK-0431J-843)
This is a study to assess the safety and efficacy of the addition of ipragliflozin once daily in Japanese participants with Type 2 diabetes mellitus (T2DM) who have inadequate glycemic control on sitagliptin, diet, and exercise…
- Trial name
- NCT02577003
- Testing
- Ipragliflozin, Sitagliptin
- Volunteers
- 143 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypertension, Diabetes
Safety Study to Lower the Risk of Heart Failure is Also Effective in Reducing Stiffness of the Arteries
The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.
- Trial name
- EFFORT (NCT00829296)
- Testing
- nebivolol, Metoprolol
- Where
- United States
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- University of Chicago
Type 2 Diabetes
Vildagliptin Versus Dapagliflozin on Glucagon
The aim of the study is to assess if vildagliptin and dapagliflozin have dissociated effects on glucagon secretion after a mixed meal ingestion in metformin-treated subjects with type 2 diabetes and whether this is associated…
- Trial name
- NCT02475070
- Testing
- Vildagliptin, Dapagliflozin
- Where
- Sweden
- Volunteers
- 28 people
- Sponsor
- Lund University
Diabetes Mellitus, Type 2
Assessing Home Food Environment and Diabetes Self-management Among Adult Type 2 Diabetes Patients
In this project the investigators examined the impact of diabetes self-management education using text messaging on increasing awareness of CVD risk perception, dietary intake, physical activity, and diabetes self-management…
- Trial name
- NCT03039569
- Testing
- Text messaging
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- University of Nebraska Lincoln
Type 1 Diabetes Mellitus
The Artificial Pancreas in Very Young Children With T1D
The suggested clinical trial is part of the KidsAP project funded by the European Commission's Horizon 2020 Framework Programme and JDRF.
- Trial name
- KidsAP02 (NCT03784027)
- Testing
- CamAPS FX, Sensor augmented therapy
- Where
- 8 sites in Austria, Germany and 2 more
- Volunteers
- 81 people
- Sponsor
- University of Cambridge
Type 2 Diabetes Mellitus
Addition of Omarigliptin (MK-3102) to Participants With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Combination Therapy With Glimepiride and Metformin (MK-3102-022)
This study will examine the safety and efficacy of the addition of omarigliptin in participants with type 2 diabetes mellitus with inadequate glycemic control on metformin and glimepiride.
- Trial name
- NCT01704261
- Testing
- Omarigliptin, Glimepiride, Metformin
- Volunteers
- 307 people
- Sponsor
- Merck Sharp & Dohme LLC
Diabetic Neuropathy
Alpha Lipoic Acid for Treatment of Diabetic Neuropathy
Patients with diabetic neuropathy and total symptoms score(TSS) >7 points were invited to this open multicenter study. Patients were free of pain medications and severe diabetic complications .Patients started alpha lipoic acid…
- Trial name
- NCT02439879
- Testing
- Alpha lipoic acid
- Volunteers
- 45 people
- Sponsor
- Universidad Popular Autónoma del Estado de Puebla
Pediatric Obesity
Family-based Lifestyle Intervention Program and Carotenoid Supplementation for Children With Obesity
This is a pilot study of children between the ages of 8 to 11 years of age who are obese and participating in an intense family based intervention with a family-focused multi-component lifestyle intervention.
- Trial name
- NCT02060279
- Testing
- Lifestyle intervention and carotenoid supplements
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Nemours Children's Clinic
Impaired Glucose Tolerance, Type 2 Diabetes
Actos Now for Prevention of Diabetes (ACT NOW)
The purpose of this study is to examine whether pioglitazone versus placebo can reduce the conversion rate of impaired glucose tolerance (IGT) to type 2 diabetes mellitus
- Trial name
- NCT00220961
- Testing
- Pioglitazone
- Where
- 8 sites in United States
- Volunteers
- 602 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Metabolic Syndrome, Type 2 Diabetes
Lifestyle Intervention for Pakistani Women in Oslo
Immigrants from South Asia in Norway have a high prevalence of type 2 diabetes and conditions related to the metabolic syndrome. It has been documented that these conditions may be prevented by changes in lifestyle.
- Trial name
- InnvaDiab (NCT00425269)
- Testing
- lifestyle intervention (diet and physical activity)
- Where
- Norway
- Volunteers
- 198 people, healthy volunteers welcome
- Sponsor
- University of Oslo
Type 2 Diabetes Mellitus
A Study to Assess the Safety, Tolerability and Glucose-Lowering Efficacy of MK-0893 in Participants With Type 2 Diabetes Mellitus (MK-0893-005)
This study will assess the safety, tolerability and glucose-lowering efficacy of MK-0893 in participants with type 2 diabetes mellitus.
- Trial name
- NCT02004886
- Testing
- MK-0893, Metformin
- Volunteers
- 74 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 2 Diabetes, Obesity
Metabolomic Analysis of Hepatic Insulin Resistance
This is a pilot study to show that it is possible to identify the specific types of fats in blood, adipose tissue, and liver tissue.
- Trial name
- NCT01833403
- Testing
- Hyperinsulinemic-euglycemic clamp
- Where
- United States
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- University of Minnesota
Pediatric Obesity
Family Focused Community Program to Prevent Type 2 Diabetes in Peripubertal Youth
Over one-third of children and adolescents are overweight and nearly 1 in 5 of them are obese. Metabolic syndrome, a strong predictor of Type 2 diabetes (T2D) and cardiovascular disease (CVD), occurs in up to 44% of obese youth…
- Trial name
- NCT02421198
- Testing
- YMCA Family Diabetes Prevention Program (YFDPP)
- Volunteers
- 47 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Diabetes Mellitus, Type 2
Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2 different doses compared to Metformin or to Sitagliptin given for 78 weeks in different modalities of treatment in patients with type 2…
- Trial name
- NCT00881530
- Testing
- BI 10773, Metformin, Sitagliptin
- Where
- 137 sites in United States, Austria and 19 more
- Volunteers
- 660 people
- Sponsor
- Boehringer Ingelheim
Type 2 Diabetes Mellitus
A Placebo Controlled Safety and Efficacy Study of INT131 Besylate in Type 2 Diabetes, With an Active Comparator
This is a 24 week study comparing the efficacy of four dose levels of INT131 besylate with pioglitazone HCl in patients with type 2 diabetes.
- Trial name
- NCT00631007
- Testing
- INT131 besylate, Pioglitazone HCl
- Where
- 66 sites in United States, Mexico
- Volunteers
- 367 people
- Sponsor
- InteKrin Therapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.